Lamictal (lamotrigine): Product packaging change notification
The packaging of Lamictal (lamotrigine) 25 mg, 50 mg, and 100 mg chewable/dispersible tablets has changed. There have been no changes to the product manufacturer, formulation, or method of manufacture.
Background
GlaxoSmithKline (GSK) has notified us that the packaging of Lamictal (lamotrigine) 25 mg, 50 mg, and 100 mg chewable/dispersible tablets has changed to a new child-resistant safety foil packaging.
No changes have been made to the formulation of Lamictal (lamotrigine) 25mg, 50mg and 100mg chewable/dispersible tablets.
Lamictal 2mg and 5mg, which are in bottle packaging, are not affected.
Affected product
- Chemical: lamotrigine
- Presentation: Tab chewable/dispersible 25, 50 and 100 mg
- Brand: Lamictal
- Supplier: GSK
Schedule listing for Lamotrigine(external link)
Packaging change patient leaflet
Product packaging change notification - GSK
- GSK letter to pharmacists about Lamictal changes [PDF 84 KB]
Who to contact
For further queries regarding Lamictal (lamotrigine), please contact GSK Medical Information at 0800 800 500 or mel.australia-medinfo@gsk.com.